What Johnson & Johnson Medtech does

Johnson & Johnson MedTech is the medical-technology division of Johnson & Johnson (NYSE: JNJ), operating four global franchises — Cardiovascular & Interventional Solutions (Biosense Webster in electrophysiology, Cerenovus in neurovascular stroke, plus the acquired Abiomed heart-pump and Shockwave intravascular lithotripsy businesses, and Laminar for left-atrial-appendage management), Surgery (Ethicon sutures, energy devices, staplers, and the investigational OTTAVA soft-tissue surgical robot), Orthopaedics (DePuy Synthes joint reconstruction, trauma, spine, sports medicine, and the VELYS digital-surgery platform with FDA-cleared robotic and AI-assisted navigation), and Vision (TECNIS IOLs and ACUVUE contact lenses). The division serves hospitals, health systems, and specialty surgical/electrophysiology/cardiac centres across more than 60 countries via a direct enterprise field-sales model organised by clinical specialty.

The portfolio is built around proprietary device platforms whose installed bases generate recurring consumable revenue: the CARTO 3 mapping system with VARIPULSE and QDOT MICRO ablation catheters; Shockwave IVL for calcified coronary and peripheral artery disease; the Impella family of miniaturised heart pumps; TRUFILL n-BCA and CereGlide aspiration catheters for stroke; and Ethicon energy-based and stapling systems. Software and AI are increasingly embedded — VELYS Hip Navigation with AI Assistance automates landmark identification, and CARTO 3 integrates AI-enabled cardiac mapping with pulsed field ablation. R&D and clinical evidence are anchored in IDE trials and registries (FORTE, MEMBRANE, DISRUPT BTK II, OMNY-AF) and in partnerships with NVIDIA (Isaac for Healthcare, GR00T, Cosmos) and AWS (Polyphonic AI Fund for Surgery).

The business model is enterprise medical-device sales plus recurring consumables, services, and professional education. Capital equipment and implants are sold through direct multi-year hospital and GPO contracts, while single-use catheters, staples, and ablation devices drive repeat revenue per procedure. Education and demand generation are delivered through the Johnson & Johnson Institute, which trains more than 125,000 clinicians annually, and through clinical-evidence publication at major cardiology and surgery congresses. The company is financed via Johnson & Johnson's corporate treasury — notable recent capital deployment includes the $16.6 billion Abiomed acquisition (2022), $400 million Laminar deal (2023), and $13.1 billion Shockwave Medical acquisition (2024). In October 2025 J&J announced plans to separate the DePuy Synthes orthopaedics business (~30% of MedTech revenue) to focus management and capital on cardiovascular growth, and effective January 1, 2026 MedTech shifted from a regional to a business-unit-led operating model.

Name

Johnson & Johnson Medtech

Legal name

Medical Devices Business Services, Inc.

Website

https://jnjmedtech.com

Company type

Public

Founded year

1886

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Johnson & Johnson MedTech is the medical-technology division of Johnson & Johnson, developing and selling cardiovascular, surgical, orthopaedic, and vision devices and implants — including electrophysiology ablation, intravascular lithotripsy, heart pumps, surgical robotics, and digital surgery platforms — to hospitals and specialty centres in 60+ countries via direct enterprise sales and recurring consumables.

Ownership category

akta.pro rank

Product category

Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)

akta.pro secondary industries

Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ), Surgical Navigation, Robotics & Patient-Matched Instrumentation (Ortho/Spine) (HLAHAEAL), Single-Use Surgical Devices & Procedure Packs (Disposable instruments, drapes, kits) (HLAHADAM), First Aid & Wound Care (Bandages, Dressings, Antiseptics, Burn Care) (CRADAMAB)

Keywords

• Medical device manufacturing
• Cardiovascular intervention
• Orthopaedic implants
• Surgical robotics
• Electrophysiology ablation

Headquarters

HQ city

Warsaw

HQ country

United States

HQ region

North America

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Marketing or Sales, Personnel, Infrastructure

Revenue model

1. Medical Device and Implant Sales: Johnson & Johnson MedTech generates the majority of its revenue through the sale of medical devices, implants, and capital equipment to hospitals and healthcare providers globally. Product categories include cardiovascular devices, surgical instruments, orthopaedic implants, and vision products. Revenue is generated through both direct hospital contracts and distributor relationships.
2. Surgical Consumables and Procedure Kits: Recurring revenue from single-use consumables, staple line reinforcement, surgical energy devices, aspiration catheters, ablation catheters, and other procedure-specific products used in conjunction with capital equipment platforms.
3. Service, Training, and Support Contracts: Revenue from the Johnson & Johnson Institute providing professional education, clinical training, and ongoing technical support services for healthcare professionals using the company's technology platforms.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Johnson & Johnson MedTech designs, manufactures, and sells medical devices, implants, and capital equipment across four platforms: cardiovascular intervention (electrophysiology mapping/ablation, intravascular lithotripsy, heart pumps, neurovascular stroke devices), surgery (energy-based devices, stapling, suturing, surgical robotics), orthopaedics (joint reconstruction, trauma fixation, digital surgery), and vision care (IOLs, contact lenses). It also sells single-use consumables, procedure kits, and provides professional education and clinical training through the Johnson & Johnson Institute.

Product overview

Johnson & Johnson MedTech operates as a diversified medical technology company organized around several major business units: Biosense Webster (electrophysiology), Cerenovus (neurovascular/stroke), DePuy Synthes (orthopaedics), Ethicon (surgery), and Mentor (breast implants). The portfolio includes interventional solutions for cardiovascular disease (Impella heart pumps, Shockwave IVL, VARIPULSE PFA), surgical robotics (OTTAVA), digital surgery platforms (VELYS), and traditional surgical instruments. Major acquisitions include Shockwave Medical ($13.1B, 2024) and Laminar ($400M, 2023). The company focuses on smarter, less invasive, more personalized treatments across cardiovascular, surgical, orthopaedic, and vision care.

Differentiator

Problem solved

Functional benefit

Brands

• Biosense Webster: Cardiac electrophysiology mapping and ablation solutions for treating cardiac arrhythmias
• Cerenovus
• DePuy Synthes
• Ethicon
• Mentor
• VELYS Digital Surgery
• OTTAVA Robotic Surgical System
• Varipulse Platform
• Shockwave IVL

Products and services

• OTTAVA Robotic Surgical System Soft-tissue surgical robot with table-integrated four-arm design for general surgery procedures including gastric bypass, gastric sleeve, and hernia repair; FDA de novo application submitted.
• CARTO 3 System AI-enabled cardiac mapping and navigation system used in electrophysiology procedures, integrating pulsed field ablation technology for atrial fibrillation treatment.
• VARIPULSE Platform Pulsed field ablation (PFA) system for treatment of drug-refractory paroxysmal atrial fibrillation, featuring real-time visualization and immediate feedback during procedures.
• Omnypulse Platform Investigational pulsed field ablation platform for atrial fibrillation showing 100% acute procedural success in OMNY-AF study; not yet FDA-approved.
• QDOT MICRO Catheter Very high power, short duration ablation catheter with micro-electrodes and accurate temperature sensors enabling zero-fluoro ablation procedures on the CARTO 3 Mapping System.
• CereGlide Aspiration Catheters Aspiration catheters for ischemic stroke treatment featuring proprietary variable-stiffness construction, hydrophilic coating, and TruCourse technology for trackability; includes CereGlide 42, CereGlide 57, and InnerGlide 7 delivery aid.
• Impella Heart Pumps Miniaturized heart pump technology for temporary mechanical circulatory support, including Impella RP with SmartAssist and Impella RP Flex with SmartAssist devices.
• TRUFILL n-BCA Liquid Embolic System Liquid embolic system for embolization procedures, including FDA-approved use for middle meningeal artery embolization to treat symptomatic chronic subdural hematoma.
• VELYS Digital Surgery Connected digital surgery platform powered by data insights for orthopaedic procedures, including VELYS Hip Navigation with AI Assistance and the VELYS surgical robot for spine.
• Shockwave IVL System Intravascular lithotripsy technology using acoustic waves to modify calcified arterial lesions before stenting, applied for coronary and peripheral artery disease treatment.
• VOLT Plating System Plating system for wrist and proximal humerus procedures.
• KINCISE 2 System Automated surgical impactor approved for knee and hip revision procedures.
• ECHELON ENDOPATH Bioabsorbable Staple Line Reinforcement Bioabsorbable staple line reinforcement device for bariatric surgeries.
• Shockwave C2 Aero Coronary IVL Catheter Next-generation intravascular lithotripsy catheter for coronary applications, featuring improved deliverability and lesion crossing capabilities.
• THERMOCOOL SMARTTOUCH SF Platform Dual energy cardiac ablation platform providing radiofrequency ablation capabilities for electrophysiology procedures.
• Laminar LAAX Technology Left atrial appendage elimination technology acquired as part of the Laminar acquisition to reduce stroke risk in atrial fibrillation patients.

Quantifiable outcome

• DISRUPT BTK II study showed high rates of limb salvage, symptom relief, and vessel patency at one year for below-the-knee IVL treatment of peripheral artery disease
• +5 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature7 records

Partnerships

Ten partnerships are on record, tiered minor and core.

• Getinge ABminorOthers · 9 April 2026Getinge AB initiated legal action against Johnson & Johnson MedTech's Abiomed subsidiary alleging patent infringement related to blood pump technology. A Massachusetts federal judge refused to dismiss the claims, continuing the patent dispute.
• NVIDIA (GTC 2026)coreTechnology or Integration · 16 March 2026At NVIDIA GTC 2026, Johnson & Johnson MedTech was highlighted as a healthcare partner in NVIDIA's physical AI ecosystem, alongside CMR Surgical and Medtronic. NVIDIA announced expanded Isaac GR00T robotics models and Cosmos world foundation models for healthcare robotics development and simulation.
• Pacira BioSciencesminorGTM or Marketing Partner · 11 March 2026Expanded partnership with Pacira BioSciences to significantly expand ZILRETTA promotional efforts, with a goal to triple ZILRETTA's reach. J&J MedTech is leveraging its commercial infrastructure to increase ZILRETTA adoption across the orthobiologics space.
• LG ChemminorGTM or Marketing Partner · 19 November 2025Partnership with LG Chem to commercialize EXPAREL and ZILRETTA in Asia Pacific countries including South Korea and Thailand starting in 2027, extending J&J MedTech's pharmaceutical partnership reach into new geographic markets.
• IRCAD North AmericaminorStrategic or Co-development Partner · 1 September 2025Johnson & Johnson collaborated with IRCAD North America to advance surgical training and education, providing clinicians with access to cutting-edge simulation and hands-on training resources.
• NVIDIAcoreTechnology or Integration · 1 July 2025Johnson & Johnson MedTech partnered with NVIDIA to advance robotics development using the NVIDIA Isaac for Healthcare platform, integrating AI capabilities into J&J's surgical robotics ecosystem. This collaboration enables enhanced surgical data analysis and simulation capabilities through NVIDIA's physical AI and Isaac simulation frameworks.
• Amazon Web Services (AWS)coreTechnology or Integration · 1 July 2025AWS co-founded the Polyphonic AI Fund for Surgery alongside Johnson & Johnson MedTech and NVIDIA. AWS provides cloud computing infrastructure, technical resources, and compliant datasets to selected participants in the AI surgery innovation program.
• Stryker, Boston Scientific, Smith+Nephew (competitive M&A landscape)minorOthers · 10 April 2025Market context: Between April and October 2025, Stryker, Boston Scientific, Smith+Nephew, and Johnson & Johnson MedTech each completed acquisitions of digital health and AI-enabled implant startups, indicating an industry-wide consolidation trend toward AI-integrated implant technologies.
• Shockwave MedicalcoreStrategic or Co-development Partner · 5 April 2024Johnson & Johnson announced the acquisition of Shockwave Medical for approximately $13.1 billion (cash payment of $335 per share), completed on May 31, 2024. The acquisition integrates Shockwave's unique intravascular lithotripsy (IVL) platform for treating calcified coronary and peripheral artery disease into Johnson & Johnson MedTech's cardiovascular portfolio, significantly expanding J&J's presence in high-growth cardiovascular intervention markets.
• Laminar, Inc. (acquired from Santé Ventures)coreStrategic or Co-development Partner · 30 November 2023Johnson & Johnson MedTech acquired Laminar, Inc. for $400 million upfront plus future milestone payments. Laminar developed atrial fibrillation treatment solutions targeting the left atrial appendage to reduce stroke risk, with an FDA-approved device for its pivotal study. The acquisition expands J&J's structural heart and left atrial appendage management portfolio.

Scale indicators9 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• Medtronic: Diversified medical device leader with overlapping portfolios in cardiac rhythm management, cardiovascular intervention, surgical robotics (Hugo), and neurovascular. Operates as a direct large-cap peer to J&J MedTech across multiple franchises.
• Stryker: Major competitor in orthopaedics, surgical equipment, and digital surgery/robotics (Mako). Overlaps directly with J&J MedTech's DePuy Synthes and Ethicon businesses, and competes in the same AI/digital implant M&A landscape.
• Abbott Laboratories: Diversified medical device peer with strong cardiovascular franchises (cardiac rhythm, structural heart, vascular) that compete head-to-head with J&J MedTech's Biosense Webster and Shockwave businesses.
• Becton, Dickinson and Company (BD): Major medical device and surgical supplies manufacturer with overlapping portfolios in surgical instruments, biosciences, and interventional solutions, comparable to parts of J&J MedTech's Ethicon and Cerenovus franchises.

Direct peers

• Intuitive Surgical: Dominant soft-tissue surgical robotics incumbent (da Vinci, Ion). Direct competitor to OTTAVA as J&J MedTech's investigational robotic platform advances toward commercialization.
• Penumbra: Specialist neurovascular and peripheral vascular thrombectomy/aspiration peer that directly competes with Cerenovus's CereGlide stroke portfolio and shares similar endovascular stroke workflow positioning.
• Smith+Nephew: Orthopaedics, sports medicine, and advanced wound management peer that competes with DePuy Synthes and Ethicon wound closure portfolios. Also actively acquiring digital surgery/AI implant startups.
• Boston Scientific: Direct peer in cardiovascular intervention (Watchman left atrial appendage closure, pulsed field ablation with FARAPULSE) and endoscopy/surgery. Closely comparable to J&J MedTech's cardiovascular and peripheral vascular franchises.
• Edwards Lifesciences: Focused cardiovascular peer in structural heart (TAVR/surgical valves) and critical care monitoring. Highly relevant comparison point for the post-orthopaedics-separation J&J MedTech cardiovascular thesis.
• Zimmer Biomet: Pure-play orthopaedics competitor with overlapping joint reconstruction, trauma, and digital surgery (ROSA robotics) offerings that directly compete with DePuy Synthes and VELYS platforms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/jnj-medtech-pt
• Xx.com/jnjmedtech

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Johnson & Johnson Medtech